我國以技術轉移建立現階段進口疫苗生產技術之成本分析

本研究從成本分析的角度與衛生決策單位的立場，評估相較於現行外購政策，我國是否值得以技術轉移方式建立麻疹／德國麻疹／腮線炎三合一疫笛(MMR)、口服小兒痳痹疫苗(OPV)、白喉／百日咳／破傷風三合一疲苗(DPT/DTaP)、及B型肝炎疫苗(HBV)的生產技術。評估的方案有四種，分別是由衛生署預防醫學研究所引進技衍生產、由民間疫苗廠引進生產、由預研所引進後轉移民間生產、與維持現狀。結果顯示政府衛生防疫單位在未來八十三至九十二年若繼續維持外購政策，對於MMR、OPV、DPT/DTaP、和HBV四種疫苗，總採購經費若以八十三年幣值為塞準，共需43.4億元。而三種自製方案對於衛生單位未來十年的相關支出，皆少於目前維持外購的方式。差距從預研所主導的減少8.9億元，到由民間自行引進的減少2.4億元。不過敏感度分析結果顯示，若未來實際技術取得成本增加或經營效率祇使得產銷費用過高，則自製方案便反而會增加衛生單位的經費支出。

關鍵字

疫苗政策；疫苗自製；成本分析

並列摘要

We conducted this cost-effective analysis comparing the future alternatives of procurement vs. domestic production of vaccines from the governmental perspective. Three alternatives were considered to build up domestic capacity for vaccine production: (1) strengthening the National Institute of Preventive Medicine(NIPM) of vaccine production capacity, (2) strengthening the private industry of vaccine production capacity, or (3) strengthening the private industry of vaccine production capacity, but with assistance of NIPM in research & development. Under the current baseline policy which imports vaccines from abroad, the total expenditure of purchasing MMR, OPV, DTaP, and HBV vaccines for public sector from 1994 to 2003 was calculated to be NT$ 4.34 billion in 1994-dollar. Over the incoming 10 years, all three alternatives, would result in a saving of vaccine expenditure, ranging from NT$ 0.24 billion less by the second alternative to NT$ 0.89 billion less by the first one. However, the sensitivity analysis indicates that the most important determinant factor would be the cost of technology transfer as well as that of sales & distributions of vaccine in the future which would greatly alter the results of our analysis in which higher cost might incur with the self-production of vaccine.

並列關鍵字

Vaccine Policy ； Vaccine Production ； Cost Analysis

被引用紀錄

陳修聖（2005）。我國醫療機構投資體外震波碎石機之研究〔碩士論文，國立臺灣大學〕。華藝線上圖書館。https://doi.org/10.6342/NTU.2005.02960

國際替代計量

我國以技術轉移建立現階段進口疫苗生產技術之成本分析

全文下載

主題瀏覽